Most Recent Articles by Hannah Dellabella
HCV viral eradication resulted in improved left ventricular diastolic dysfunction.
Real-world effectiveness of elbasvir/grazoprevir for HCV GT1 or GT4 is similar in the US Veterans Affairs-treated population as compared with those reported in clinical trials.
CMS issued a proposal to update payment policies, quality provisions, and payment rates for services under the Medicare Physician Fee Schedule on or after January 1, 2019.
Treatment with sofosbuvir/velpatasvir/voxilaprevir led to improvements in patient-reported outcomes in patients who had previously not responded to another DAA regimen.
Non-targeted, opt-out testing for HCV infection can be successfully implemented in the ED setting.
More Articles by Hannah Dellabella
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Clinicians Warn That Zika Virus May Still Be an Area of Concern for Travelers
- Inappropriate Prescribing of Antibiotics High in Urgent Care Centers
- Fixed-Dose Bictegravir Regimen: A Safe Alternative in Adults With HIV-1
- Point-Counterpoint: Should We Implement Needle Exchange Programs for the Prevention of Hepatitis C Virus?
- FDA: Vibrio parahaemolyticus Illnesses Tied to Fresh Crab Meat From Venezuela
- Universal Purchase Programs in the United States May Not Effectively Increase Vaccination Rates
- Tick-Caused Meat Allergy on the Rise in the United States
- Prognostic Biomarkers to Guide Antibiotic Therapy in Critically Ill Patients
- Sofosbuvir/Velpatavir Effective for HCV-Infected Liver Transplant Recipients
- Should Metronidazole Be Recommended for Mild Clostridium difficile Infections?
- Same-Day ART Initiation in HIV+ Pregnant Women Does Not Worsen Outcomes
- Novel Nanodiagnostic Panel May Reduce Empiric Antifungal Use in High-Risk Candidemia
- Antimicrobial Lock Solutions Are Cost-Effective for Preventing Central Line-Associated Bloodstream Infections
- Predictors of Influenza Vaccine Acceptance in Inflammatory Rheumatic Diseases
- Pegylated Interferon, Ribavirin May Improve LV Diastolic Dysfunction in Chronic Hepatitis C